Page 321 of 1,034: studies 3,201 to 3,210 of 10,336, newest first. Back to the depression overview
The Journal of Nervous and Mental Disease August 1, 2008
Mindfulness predicts relapse/recurrence in major depressive disorder after mindfulness-based cognitive therapy.
Psychotherapy and Psychosomatics July 4, 2008
Mindfulness-based cognitive therapy for treatment-resistant depression: a pilot study.
Journal of Consulting and Clinical Psychology June 2008 Alex J Zautra, Mary C Davis, John W Reich et al.
This research examined whether cognitive behavioral therapy and mindfulness interventions that target responses to chronic stress, pain, and depression reduce pain and improve the quality of everyday life for adults with rheumatoid arthritis (RA). The 144 RA participants were clustered into groups of 6-10 participants and randomly assigned to 1 of 3 treatments: cognitive behavioral therapy for...
Psychopharmacology June 2008 Piotr Popik, Tomasz Kos, Magdalena Sowa-Kućma et al.
We investigated the immediate and enduring effects of ketamine in behavioral and neurochemical assays predictive of antidepressant activity. One week after a single administration of ketamine (50-160 mg/kg), otherwise experimentally naive rats and mice were tested either in the forced swim test (FST) or the tail suspension test (TST). Other mice were also tested twice in the FST: immediately...
The World Journal of Biological Psychiatry May 12, 2008 Michael Liebrenz, Rudolf Stohler, Alain Borgeat 73 citations
BACKGROUND: The intravenous administration of ketamine, an N-methyl-D-aspartate receptor antagonist, results in a great improvement of depression symptoms, but it is not clear for how long. This single-case trial was conducted to explore the duration of improvement and the effects of a second administration on the clinical outcome. METHODS: In an open label trial, a 55-year-old male patient...
Current Psychiatry Reports December 2007 Sungho Maeng, Carlos A. Zarate
In this article, we first review a study showing that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA...
Journal of Sleep Research September 1, 2007 Mariana Szklo‐coxe, Terry Young, Laurel Finn et al.
SummarySleep disturbances are important correlates of depression, with epidemiologic research heretofore focused on insomnia and sleepiness. This epidemiologic study’s aim was to investigate, in a community sample, depression’s relationships to other sleep disturbances: sleep paralysis (SP), hypnagogic/hypnopompic hallucinations (HH), cataplexy – considered rapid eye movement‐related...
Psychological Medicine July 1, 2007 Louisa Degenhardt, Chris Tennant, Stuart Gilmour et al.
The aim was to examine the temporal relationships over 10 months between cannabis use and symptoms of psychosis and depression in people with schizophrenia and related disorders. The design was a prospective study of 101 patients with schizophrenia and related disorders who were assessed monthly over 10 months on medication compliance, cannabis and other drug use, symptoms of depression and...
Aging & Mental Health May 1, 2007
Mindfulness-based cognitive therapy for recurring depression in older people: a qualitative study.
Swiss Medical Weekly April 21, 2007 Michael Liebrenz, Alain Borgeat, R Leisinger 75 citations
BACKGROUND: Recently, reports from North America have indicated that the intravenous infusion of ketamine hydrochloride (an N-methyl-d-aspartate receptor antagonist) results in a sudden and robust improvement of depression symptoms. OBJECTIVE: To corroborate antidepressant effectiveness of IV ketamine in a patient with a co-occurring substance use disorder for the first time in a European...